Response to 'Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest'

N Bi¹, J Liang¹, L Wang¹

Affiliations

¹ Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Free article

Comment

N Bi et al. Ann Oncol. 2017.

Free article

. 2017 Dec 1;28(12):3101-3103.

doi: 10.1093/annonc/mdx533.

N Bi¹, J Liang¹, L Wang¹

¹ Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

No abstract available

Comment on

Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L. Liang J, et al. Ann Oncol. 2017 Apr 1;28(4):777-783. doi: 10.1093/annonc/mdx009. Ann Oncol. 2017. PMID: 28137739 Clinical Trial.
Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest.
Manapov F, Eze C. Manapov F, et al. Ann Oncol. 2017 Sep 1;28(9):2319-2320. doi: 10.1093/annonc/mdx254. Ann Oncol. 2017. PMID: 28911081 No abstract available.